obesity drug news today glp-1 2025 Market GLP-1 Weight Loss Drug Enforcement
Description
Therapists work with patients to challenge distorted beliefs about food and body image, ultimately promoting long-term recovery
Why 2026 could be a big year for GLP-1s The next wave of obesity medications isnt just more GLP-1. Many candidates are designed to improve results by combining GLP-1 with other hormone pathways that influence: Appetite and satiety signaling in the brain Gastric emptying and cravings Energy expenditure and fat metabolism Insulin sensitivity and cardiometabolic risk factors That means the future may include: Oral (pill) GLP-1 therapy for weight management Combination therapies that intensify satiety (like amylin-based add-ons) Multi-agonist incretins (triple-hormone approaches) 1) Orforglipron (oral GLP-1 pill) a likely 2026 headliner What it is: Orforglipron is an oral, small-molecule GLP-1 receptor agonist being developed by Eli Lilly for obesity and type 2 diabetes
Category 3: Substances with insufficient information to permit evaluation
Quan H, Sundararajan V, Halfon P, et al
Whats more, over a dozen potential new GLP-1 RAs are being developed [archived link]
The most noticeable differences between the unmatched GLP-1 RA group and the DPP-4i group were sex (43.1% vs
